Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1
20
about 1.6 years
1–25
1 site in CA
Why this study is shown
What this study is about
This trial is testing the safety and how well a new treatment, autologous CD22 CAR T cells, works when given after a commercial CAR T cell therapy called Tisagenlecleucel. The goal is to find out if this new treatment can be safely used in children and young adults with relapsed or refractory B-cell leukemia.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CD22CART infusion
- 2.Take Tisagenlecleucel
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
tisagenlecleucel (CAR T-cell therapy targeting CD19 on leukemia cells)
infusion
Oncology